Robert J. Matusik

Robert J. Matusik

Auto-generated profile, based on publicly available information

Robert J. Matusik

Department of Urology Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 July 2021 in The Prostate
Verified
Journal Article
Closed access
PDF file
RJRenJie Jin
RenJie Jin
DSDouglas W. Strand
Douglas W. Strand
CFConnor M. Forbes
Connor M. Forbes
TCThomas Case
Thomas Case
JCJustin M. M. Cates
Justin M. M. Cates
RMRobert J. Matusik
Robert J. Matusik


17 December 2024 in Science Signaling
Verified
Journal Article
Closed access
SCSherly I. Celada
Sherly I. Celada
GLGuoliang Li
Guoliang Li
LCLindsay J. Celada
Lindsay J. Celada
TKThanigaivelan Kanagasabai
Thanigaivelan Kanagasabai
WLWenfu Lu
Wenfu Lu
ZCZhenbang Chen
Zhenbang Chen
Resistance to androgen receptor (AR)–targeted therapies for prostate cancer (PCa) is characteristic of an aggressive subtype called castration-resistant prostate cancer (CRPC) and is often associated with tumor relapse. Both relapse and poor prognosis in patients with CRPC are associated with increased abundance of the E3 ubiquitin ligase SKP2. Therefore, we investigated the therapeutic potential of combined inhibition of AR and SKP2 for CRPC. We found that combined targeting of AR and SKP2 with small-molecule inhibitors decreased proliferation in two CRPC cell lines in culture and in xenografts in humanized mice. Furthermore, combined therapy in mice markedly decreased the growth of Pten/Trp53 double-knockout tumors, a particularly invasive model of CRPC, whereas disruption of either AR or SKP2 alone only modestly suppressed their growth. Mechanistically, the inhibition of SKP2 in CRPC cells induced autophagy-dependent apoptosis and promoted luminal-associated phenotypes, which promoted responsiveness to AR-targeted therapy. These effects were further enhanced by coinhibition of AR and were not induced by the AR inhibitor alone. Our findings indicate that targeting both AR and SKP2 signaling pathways is necessary to treat CRPC.

Verified
Journal Article
Open access
PDF file
Josiah OchiengJosiah Ochieng
Josiah Ochieng
OKOlga Korolkova
Olga Korolkova
GLGuoliang Li
Guoliang Li
RJRenjie Jin
Renjie Jin
ZCZhenbang Chen
Zhenbang Chen
OOOgunkua Olugbemiga
Ogunkua Olugbemiga
The present studies were conducted to evaluate key serum proteins and other components that mediate anchorage-independent growth (3-D growth) of LNCaP prostate cancer cells as spheroids. The cells were cultured on ultra-low attachment plates in the absence and presence of fetuin-A and with or without extracellular vesicles. The data show that fetuin-A (alpha 2HS glycoprotein) is the serum protein that mediates 3-D growth in these cells. It does so by sequestering extracellular vesicles of various sizes on the surfaces of rounded cells that grow as spheroids. These vesicles in turn transmit growth signals such as the activation of AKT and MAP kinases in a pattern that differs from the activation of these key growth signaling pathways in adherent and spread cells growing in 2-D. In the process of orchestrating the movement and disposition of extracellular vesicles on these cells, fetuin-A is readily internalized in adhered and spread cells but remains on the surfaces of non-adherent cells. Taken together, our studies suggest the presence of distinct signaling domains or scaffolding platforms on the surfaces of prostate tumor cells growing in 3-D compared to 2-D.

1 July 2012 in Journal of Urology
Verified
Journal Article
Closed access
DDDavid J. DeGraff
David J. DeGraff
RMRobert J. Matusik
Robert J. Matusik